|
|
Method of treating oral proliferative verrucous leukoplakia 30 minutes before a cryodestruction procedure, 1% nicotinic acid 0.5 ml is introduced under the mucous membrane of a leukoplakia lesion by means of a tuberculin syringe. |
|
|
Carboxylic acid derivatives containing 2,5-substituted oxazolopyrimidine ring Invention refers to oxazolopyrimidine compounds of formula I in any of its stereoisomer forms or its physiologically acceptable salt, wherein A is specified in NH, O and S; X is specified in (C1-C6)-alkanediyl, (C2-C6)-alkenediyl, and (C1-C6)-alkanediyloxy, wherein oxygen atom of (C1-C6)-alkanediyloxy group is related to the group R2; R1 is specified in hydrogen and (C1-C4)-alkyl; R2 is specified in phenylene, which is optionally substituted in one or more carbon atoms in the ring by identical or different substitutes R22; R3 is specified in (C1-C6)-alkyl optionally substituted by 1-3 fluorine atoms, or R3 is a residue of a saturated or unsaturated 5-merous - 10-merous monocyclic or bicyclic ring, which contains 0, 1 or 2 heteroatoms in the ring specified in N, O and S, and represents cyclopentyl, indanyl, phenyl, naphthyl, thiazole, isothiazole, pyridyl, benzothiazole or quinoline, and wherein a residue of the ring is optionally substituted in one or two carbon atoms in the ring by identical or different substitutes R31; R22 is specified in (C1-C4)-alkyl optionally substituted by 1-3 fluorine atoms; R31 is specified in halogen, (C1-C4)-alkyl optionally substituted by 1-3 fluorine atoms, (C1-C4)-alkyloxy optionally substituted by 1-3 fluorine atoms, and (C1-C4)-alkyl-S(O)m- optionally substituted by 1-3 fluorine atoms; m is equal to 0. The invention also refers to a pharmaceutical composition containing the compounds of formula I, and to a method for producing the compounds of formula I. |
|
|
Synergistic combinations of carotenoids and polyphenols Invention relates to the pharmaceutical industry, namely to a therapeutic anti-inflammatory composition, which contains one or several polyphenols and two or more carotenoids, which are selected from the group, consisting of lutein, lycopene and β-carotene, where the polyphenols are selected from the group consisting of carnosic acid, quercetin, resveratrol and gallic acid, in a specified quantity; to the method of inhibition or reduction of superoxide-ions formation, NO, TNF-α and/or PGE2 in a subject-mammal, which the said composition is introduced to; to the method of treating pathological conditions, in which superoxide-ions, NO, TNF-α and/or PGE2 function as a modulator or mediator of the said condition of the subject-mammal, which the said composition is introduced to; to the application of a combination of one or several polyphenols and two or more carotenoids, selected from the group, which consists of lutein, lycopene and β-carotene, where the polyphenols are selected from the group, consisting of carnosic acid, quercetin, resveratrol and gallic acid, in a specified quantity. |
|
|
Invention refers to medicine and describes a method of treating a pathological condition caused by free radicals in a patient involving administering the first ingredient into the patient, wherein the first ingredient is a manganese complex of Formula I in an amount effective for treating the pathological condition, and the second ingredient, which is other than the manganese complex of Formula I in an amount effective to reduce manganese absorption by the patient's brain as compared to the first ingredient if administered without the second one, wherein the second ingredient is administered in an amount from approximately 1 to 20 mcmole/kg, wherein the first ingredient and the second ingredient are taken in the first ingredient/second ingredient ratio from approximately 1:1 to 1:10 of body weight, and wherein the second ingredient is supposed to be administered optionally with one or more physiologically acceptable carriers and/or additives. |
|
Invention relates to crystals of solvate of trityl olmesartan medoxomil with acetone, which comprise 1 mol of acetone per 1 mol of of trityl olmesartan medoxomil, versions of methods of thereof obtaining, as well as to method of obtaining olmesartan medoxomil with application of crystals of solvate of trityl olmesartan medoxomil with acetone. |
|
Agent possessing endothelium protective activity Invention refers to using n-thyrozol as an endothelium protective agent. |
|
Antioxidant composition containing retinol acetate in an amount of 1,650 International units (0.568 mg) - 3,300 International units (1.135 mg), α-tocopherol acetate 7.5-10 mg, ascorbic acid 35-50 mg, thiamine hydrochloride 0.581-1.0 mg, riboflavin 1.0-1.27 mg, pyridoxine hydrochloride 2.5-5.0 mg, folic acid 50-100 mg, lipoic acid 1-2 mg, ferric sulphate 2.5-5.0 mg, copper sulphate 75-400 mcg, methionine 50-100 mg, selenium 25-50 mcg is prescribed across contraception. The antioxidant composition is administered once a day, orally after meals over a period of 30 days. After 30-day pauses, the therapeutic course is repeated five times. |
|
|
Therapeutic agent (y-39983) for corneal endothelial dysfunction Group of inventions refers to medicine. A therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide <Y-39983> or its pharmacologically acceptable salt (compound (Ia)) as an active ingredient, an agent for corneal endothelial cell adhesion stimulation containing the compound (Ia), a corneal endothelial cell culture medium containing the agent for adhesion stimulation, a corneal graft for endothelial keratoplasty comprising corneal endothelial cells, a frame and the compound (Ia), and a method for producing a corneal endothelial preparation involving the stage of corneal endothelial cell culture with the use of the culture medium. |
|
Invention relates to veterinary, in particular to aspects, associated with cellular immunity, and describes a method for the reduction of the hormonally conditioned immunosuppressive effect of cellular immunity with homoeopathic medications in vitro. The method is characterised by the fact that the hormonal medication glycortin-20 is added to a leukocytic suspension, with the further introduction after incubation of a homoeopathic medication, diluted in physiological solution in a selected from Phytolac C6 or C200, Arsenicum album C6 or C12 or C30 or C200, Lachesis D15 or C12 or C30 or C200, Aconite C6 or C12 or C200, Belladonna C30, Nux vomica C6, Phenogrossi C6 or C12, Conium C30, Arnica C12, Ipecacuanha C6 or C200 dilution, then after incubation introduced is a suspension of microorganisms of a reference strain of Staphylococcus albus No 182, which contains 109 CFU/ in 1 ml of physiological solution, then after incubation smears of blood are fixed in alcohol-formalin, taken in a ratio of 1:9, which contains 40% formalin solution and 96° alcohol for 10 minutes, and then stained by Romanowski-Giemsa for 30 minutes. |
|
|
Method for producing biological stimulator Invention represents a method for producing a biological stimulator containing 50% of biologically active mass of male bee larvae, 49.7% of sodium chloride and 0.3& of a preserving agent consisting in the fact that the preparation is prepared by keeping bee's cells with alive 3-5-day-old male bee brood in a fridge at temperature 3-4°C for 5-6 days, opening the cells with the brood and selecting the male bee larvae of the same size in light-grey, grinding the male bee larvae in a sterile laboratory mill, diluted with 0.9% saline in ratio 1:1 and autoclaved at inner curing temperature 120°C and jacket steam pressure 1.5 atm for 1 hour, filtering the mass through 2 gauze layers into a sterile graduated bottle, reducing to initial volume with sterile 0.9% saline, adding with the preserving agent phenol, bottling into the prepared sterile flasks while observing the aseptic and antiseptic regulations, sealing the flasks tightly, autoclaved at 120°C and jacket steam pressure 1.5 atm for 20 minutes. |
|
Methods and compositions for vaccination of poultry Method comprises administering in ovo during the final quarter of the incubation period of an effective immunising dose of the immunogenic composition directly into the embryo. |
|
Herbal medicinal product having endothelioprotective activity Invention refers to pharmaceutical industry, namely to using dense extract of cowslip paigle (Primula veris L.) herb. The dense extract of cowslip paigle is effective as an endothelioprotective agent. |
|
Method for detecting and localising glial brain tumours intraoperatively Invention refers to medicine, namely to neurosurgical oncology, and can be used to detect and localise a brain tumour. A surgical intervention involves taking solution of 5-aminolevilinic acid. The tumour is removed under visual control with the use of a surgical microscope provided with a white-light source. To detect the involved brain regions, a brain region of interest is occasionally illuminated locally with laser light at wave length 405 nm. The involved region is examined simultaneously in the reflected white light and protoporphyrin IX red fluorescent light through a rejection filter lens blocking the laser light reflected from the object. Using a laser emitter at wave length in the proximity of a short-wavelength visual reception limit enables blocking the reflected laser light without loss of the white light examination. |
|
Carboxylic acid derivatives containing 2,5,7-substituted oxazole pyrimidine ring Invention relates to oxazole pyrimidine compounds of formula in any of stereomeric forms thereof or a physiologically acceptable salt thereof, where A is O; X is (C1-C6)alkanediiyl oxy; R1 is (C1-C6)alkyl; R2 is phenylene, optionally substituted at one or two ring carbon atoms with identical or different R22; R3 is (C1-C6)alkyl, optionally substituted with 1-3 fluorine atoms, or (C3-C7) cycloalkyl-CuH2u- (u is selected from 1 and 2), or R3 is a residue of a saturated or unsaturated 4-10-member monocyclic or bicyclic ring containing 0, 1, 2 or 3 identical or different heteroatoms in the ring, selected from N, O and S, and is (C4-C6)cycloalkyl, indanyl, phenylene, naphthyl, isothiazolyl, thiadiazolyl, pyridyl, benzothiazolyl, quinolinyl, tetrahydrofuranyl, where the ring residue is optionally substituted at one or more ring carbon atoms with R31 substitutes; R4 is hydrogen; R22 is (C1-C4)alkyl; R31 is selected from a group consisting of a halogen and (C1-C4) alkyl, which is optionally substituted with 1-3 fluorine atoms, (C1-C4)alkyloxy, which is optionally substituted with 1-3 fluorine atoms, and (C1-C4)alkyl-S(O)m-, wherein (C1-C4)alkyl is optionally substituted with 1-3 fluorine atoms; m equals 0. The invention also relates to a pharmaceutical composition containing a compound of formula I, and to a method of producing compounds of formula I. |
|
Method of increasing nonspecific resistance of organism in conditions of cold impact Invention relates to experimental medicine and can be applied for the increase of the nonspecific resistance of a warm-blooded organism in conditions of a cold impact. The method includes the daily introduction of a medication immediately before three-hour cooling in a climate chamber at a temperature of -15°C. The medication Remaxol is introduced intraperitoneally to rats in a dose of 100 mg/kg of weight for 6 days. |
|
Agent possessing lymphokinetic activity Invention refers to pharmaceutical industry, particularly to an agent possessing lymphokinetic activity. The agent possessing lymphokinetic activity contains dihydroquercetin and arabinogalactan in ratio (weight parts) 1:5. |
|
|
Method for saturation of porous coating of prosthetic implants Method for saturation of porous coating of prosthetic implants involves immersing a prosthetic implant into an impregnation container with medicinal solution arranged in a working chamber. Air is eliminated from the chamber by generating negative pressure to be thereafter increased. A top piece of the prosthetic implant comprising nanopores and nanochannels are connected to a rod fastener and fixed in the chamber. Air is eliminated from the chamber until the prosthetic implant is immersed into the impregnation container and simultaneously exposed to ultraviolet and infrared lights for 1.5-4 hours. Thereafter, the pressure is increased in the chamber to 1-1000 Pa, and the prosthetic implant is immersed into the impregnation chamber. The immersion is followed by mechanical percussion action on the fastener with accelerating the process of saturation of the porous structure with nanopores and nanochannels at a frequency of 100-2000 Hz. |
|
New nicotinamide derivative or salt thereof Invention refers to nicotinamide derivatives of formula (I) exhibiting the property of Syk-kinase inhibitor and to a based pharmaceutical composition. In general formula |
![Novel crystalline forms of 4,4'-[4-fluoro-7({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl} ethynyl)-2-methyl-1h-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid](http://img.russianpatents.com/img_data/1215/12159727-s.jpg)
|
Invention relates to novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diiyl]dibutanoic acid. |
|
Invention refers to medicine, namely to cardiology, and can be used to assist the haemodynamic correction of congenital heart defects in the patients with a functional single ventricle. To this effect, after the patient is disconnected from a cardiopulmonary bypass and decannulated, an infusion line is introduced to perform a hemofiltration and a modified ultrafiltration. Thereafter, protamine sulphate is administered. |
|
Method of treating anal constriction Anus is irrigated with 10% lidocaine, which is followed by administering diprospan under scar tissue by infiltrating the whole scar. A preparation dose for each injection covering an area of approximately 0.5 cm2 is 0.1 ml. A total dose makes no more than 1 ml of diprospan per one session. The sessions are performed every 4 weeks; the therapeutic course makes 3 sessions. |
|
|
Heterocyclic carboxylic acid derivatives having 2,5-substituted oxazolopyrimidine ring Invention refers to oxazolopyrimidine compounds of formula , wherein A is specified in O or S; X is specified in (C1-C6)-alkanediyl, (C2-C6)-alkenediyl and (C1-C6)-alkanediyl-oxy, wherein an oxygen atom of (C1-C6)-alkanediyl-oxy group is bound to the group R2; Y represents a 4-7-merous saturated monocyclic heterocycle; R1 represents hydrogen; R2 is specified in phenylene, which is optionally substituted by one or two identical or different substitutes R22; R3 is specified in phenylene and thiazole, wherein a ring residue is optionally substituted by identical or different substitutes R31 at one or two carbon atoms of the ring; R22 is specified in halogen and (C1-C4)-alkyl-, which is optionally substituted by 1-3 fluorine atoms; R31 is specified in halogen, (C1-C4)-alkyl and (C1-C4)-alkyloxy. The invention also refers to a method for producing the compounds of formula I and to a pharmaceutical composition applicable for activating EDG-1 receptor. |
|
(r)- and (s)-isomers of 3-methylspermidine Invention relates to novel trihydrochlorides of (R)- and (S)-isomers of 1,8-diamino-3-methyl-4-azaoctane (3-methylspermidine), corresponding to structural formulae given below and to a method for production thereof. Said compounds can be used in vitro and in vivo to investigate individual cell functions of easily interconvertible and partially interchangeable spermine and spermidine, which are vital for tumour cells and pathogenic trypanosomatids. The (R)-isomer of 3-methylspermidine trihydrochloride is the first metabolically stable functionally active spermidine mimetic. |
|
Method for intensifying neolymphoadenogenesis for increasing non-specific body resistance Patient takes herbal tea of Siberian medicinal plants in a daily dose of 0.15 mg/kg for one month containing the following medicinal plants, wt %: bergenia root - 4, sweetvetch (tick trefoil) - 4, rhodiola rosea - 2, bergenia leaves - 2, bilberry leaves - 1.6, red bilberry leaves - 1.6, currant leaves - 1.6, cinnamon rose - 1.6, thyme - 1.6 and a sorption compound of dietary fibres (wheat middling - 60, oatmeal flour - 20); that is combined with 15-20-minute applications of ozonized olive oil on the hips and inguen every second day in number of 14 procedures. |
|
Method of treatment and prevention of diseases of distal part of limbs in ungulates Treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint. |
|
Method for stimulating excised liver regeneration with l-norvaline Stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment. |
|
Invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days. |
|
|
2,5-substituted oxazolopyrimidine derivatives Invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds. |
|
Derivative of heterocyclic carbon acids, which contain 2,5,7-substituted oxazolopyrimidine ring Invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) . |
|
Medication for stimulation of metabolic processes and growth activity of calves Invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system. |
|
|
Method for increasing body adaptability under thermal stress Cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days. |
|
|
Method of complex treatment of patients with purulent-necrotic forms of diabetic foot syndrome Minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days. |
|
|
Method for surgical management of chronic periodontitis Method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together. |
|
|
To correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact. |
|
Disulphide-linked polyethylene glycol/peptide conjugates for nucleic acid transfection Invention relates to versions of a polymeric carrier molecule, a complex of a polymeric carrier with a load, a method of producing a polymeric carrier molecule, a pharmaceutical composition and a vaccine. In one of the versions, the polymeric carrier molecule has the following formula (I): L-P1-S-[S-P2-S]n-S-P3-L and additionally contains in the structure at least one amino acid component (AA)x, wherein AA is an amino acid, x is an integer selected in the range of 1 to 100. If the amino acid component (AA)x is present in the structure, then it is a linker between P1 or P3 and component L. If component L is absent, then at least one amino acid component (AA)x is part of P1 or P3. Components P1 and P3 are different or identical and are a linear or branched chain of a hydrophilic polymer of polyethylene glycol (PEG); P2 is a cationic or polycationic peptide or a protein with length of 3 to 100 amino acids, or a cationic or polycationic polymer with molecular weight of 0.5 kDa to 30 kDa; -S-S is a disulphide bond; L is an optional ligand, n denotes an integer selected from 1 to 50. According to the second version, the polymeric carrier molecule has the formula (Ia) l-P1-S-{[S-P2-S]a[S-(AA)X-S]b}-S-P3-L, where a+b=n, where n equals 1, 2, 3, 4 or 5 to 10; a is an integer selected independent of integer b in the range of 1 to 50, b is an integer selected independent of integer a in the range of 1 to 50. Separate components [S-P2-S] and [S-(AA)x-S] are present in any order in the subformula {[S-P2-S]a[S-(AA)x-S]b}. The complex of the polymeric carrier with a load is formed by the polymeric carrier molecule and a nucleic acid. A pharmaceutical composition and a vaccine include the complex of the polymeric carrier with a load and optionally a pharmaceutically acceptable carrier and/or solvent. Polymeric carrier molecules and the complex of the polymeric carrier with a load are used as a medicinal agent for treating various diseases. |
|
Opioid antagonist compounds and using them in treating sclerodermia Group of inventions refers to medicine, namely to dermatology and can be used in treating sclerodermia. Versions of the invention provide using naltrexone in treating sclerodermia. |
|
Method of recovering spleen after radiation load Method is realised by the intravenous allogeneic transplantation of multipotent mesenchymal stromal cells (MMSC) and hematopoietic stem cells (HSC) to laboratory mice one hour after irradiation. HSC are obtained from the placenta of female mice at the 14-day gestation term. MMSC are introduced in a dose of 6.5 mln cells/kg, with HSC being introduced in a dose of 400 thousand cells/kg. |
|
|
Introduction of endoscope into duodenum is realised. After that, "tight" filling of choledoch is performed through cholecystostoma with sterile solution, for instance, 0.25% Novocain. After that major duodenal papilla is catheterised and endoscopic papillosphincterotomy is carried out. |
|
|
Thiacalixarene derivatives as agent for dna delivery into cells Invention refers to thiacalixarene derivatives of general formula I , which can be used as agents for DNA delivery into eukaryotic cells. |
|
Method of treating glial brain tumours of supratentorial localisation Invention relates to medicine, namely to neurosurgery, neurooncology, and can be used for the treatment of glial brain tumours of a supratentorial localisation. For this purpose photodithazine in a dose of 1 mg/kg of body weight is introduced to a patient 2 hours before the tumour ablation. After that, surgical access to the tumour is performed. The operation wound is illuminated by blue colour with a wavelength of 400 nm, and the tumour boundaries are determined by means of fluorescence of photodithazine, selectively accumulated in the tumour tissue. The tumour is ablated under control of the tumour luminescence in blue colour with the application of an operation microscope. After that, a flexible light guide from a radiation source with a wavelength of 662 nm and power of 2.0 W with a light dispersing nozzle is placed into the tumour bed and the perifocal zone of the tumour is irradiated. The dose of irradiation is determined by the disappearance of fluorescence. |
|
|
Plasma-adapted balanced solution of electrolytes Invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate. |
|
|
Stellaria grass infusion is introduced to laboratory animals in a dose of 5 ml/kg of weight 20 minutes before irradiation in an ultraviolet chamber for 14 days daily. |
|
Using phospholipid-containing composition for removing subcutaneous fat by subcutaneous lypolysis Invention refers to medicine and can be used for making a drug for removing subcutaneous fat. That is ensured by using a composition containing: at least one phospholipid, at least one glycyrrhizic acid or a glycyrrhizic acid salt, and wherein total content of phospholipids and glycyrrhizic acid or its salts makes 2-80 wt % and a weight ratio of phospholipids and glycyrrhizic acid or its salts makes from 30:1 to 0.5:1. The composition can additionally contain additives. As phospholipid, the composition contains animal or herbal phosphatidylcholine. The composition can also contain glycyrrhizic acid or potassium, sodium, ammonium or magnesium salt of glycyrrhizic acid. As an additive, the composition contains sugar, particularly glucose, or maltose, and/or their derivatives, mannitol, sorbitol or lactose. The composition contains phosphatidylcholine in a total amount of 15 to 98 wt %, preferentially 30 to 98 wt %, more preferentially 50 to 98 wt %, especially preferentially 75 to 98 wt %, and most preferentially 75 to 90 wt % of total content of phospholipids. The composition is used in the dry form, preferentially in the form of lyophilisate prepared by freezing and drying, or in the form of a solution. The composition can contain physiologically acceptable solvents, including water, normal saline, glucose solution, such monohydric alcohols, as ethanol, 2-propanol, n-propanol, such polyatomic alcohols, as glycerol and/or propane diol, such polyglycols, as polyethylene glycol and/or Miglyol, glycerol, formal, dimethylisosorbitol, natural and synthetic oils and/or esters. Diseases of subcutaneous fatty tissue can be particularly related to local fat maldistribution. Fatty tissue tumour decomposition and reduction can be also solved. The drug can be presented in the form of cream, ointment, gel, hydrogel, lotion, paste, powder or solution. Undesired unaesthetic and pathological local fat maldistribution involve lipoedema, adipose growth, abdominal adiposis, cellulites, pseudogynecomasty, "buffalo hump" in HIV-infected patients, panniculitis or nonspecific subcutaneous fat deposition. The preparation is administered by subcutaneous, intra-abdominal, intramuscular or intravenous injection. The administration is implemented by a method specified in a group consisting of ioophoresis, electroporetion and phonophoresis. |
|
Photosensitiser for photodynamic therapy What is presented is using meso-tetra(3-pyridyl)bacteriochlorin of structural formula (I) as a near-infrared photosensitiser for a photodynamic therapy. Doses 1.0-2.5 mg/kg of the declared photosensitiser have provided 70-100% tumour growth inhibition, 80-131% increase in life expectancy and 25-100% animals' recovery by selective tumour collection and fast clearance. |
|
Fc receptor binding agents based on invariable region of immunoglobulin Presented invention refers to immunology. There are disclosed versions of a dimer compound for forming a multimer capable to reproduce the effector function of aggregated IgG with identical monomers. Each monomer of the dimer comprises: a monomer of IgG2 link region or a monomer of isoleucine zipper, dimerising each of which forms a multimerising region, and at least Fc-domain monomer containing a link region, CH2 domain and CH3 domain of IgG1. What is described is a multimer compound capable to reproduce the effector function of aggregated IgG and containing two or more dimers. There are disclosed a method for changing the immune response using the dimer or multimer, as well as a multimer-based method of treating an inflammatory disease. |
|
Product comprises Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the dilutions described below in the following ratio, in parts: Lycopodium clavatum ⌀=D1 0.004, Podophyllum peltatum ⌀ 0.003, Acidum arsenicosum ⌀=D2 0.0001, Phosphorus ⌀=D3 0.001, Thuja occidentalis ⌀ 30, Echinacea purpurea ⌀ 30, Silybum marianum ⌀ 60, Selenocysteine 0.2. |
|
Method for producing an agent for stimulating body cells involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of hydrazine hydrochloride and PEG 400; the prepared mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off; the produced solution is added with hexamethylene tetramine; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances. |
|
Method of treating combined radiation-thermal injury Invention relates to medicine and can be used for the treatment of radiation-thermal injury of an organism. For this purpose a single subcutaneous introduction of bifidumbacterin, irradiated by gamma-rays in a dose of 14.0 Gy, is carried out. Bifidumbacterin is introduced in a dose of 1.43·106 CFU/kg. After that, 10% hypericum oil is applied on the burnt region. Then a 10% hypericum cream is applied after 3-4 days. |
|
|
Method for preventing biological membrane damages Erythrocyte cell medium is added with an aqueous solution of sodium and potassium salts of humic acids prepared on brown coal of leonardite in a dose of 10.0 mg/kg. That is incubated at a temperature of 37°C for 40 minutes before treatment with acidic haemolytic. |
|
Invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula (I) X represents a C1-5-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; R1 represents a hydrogen atom or a C1-6-alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6-alkyl group, C2-6-alkenyl group, C3-6-cycloalkyl group, (C3-6-cycloalkyl)-C1-6-alkyl group, halogen-C1-6-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur/gimeracil/oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed. |
Another patent 2550829.